DCI Partners

Luca Science Inc. specializes in creating a new treatment using mitochondria, which is bioenergy itself. It is based in Japan.

K Pharma is a company focused on the research, development, manufacturing, sales, and marketing of pharmaceutical and regenerative medicine products. It specializes in creating treatments for spinal cord injuries and other neurological conditions, including cerebral infarction, by studying induced pluripotent stem cells. Through its innovative approach, K Pharma aims to advance therapeutic options for patients suffering from debilitating neurological disorders.

Elixiron Immunotherapeutics is a company developing therapeutics for cancer, neurological diseases, and inflammatory disorders.

Renascience is a pharmaceuticals company focused on the research and development of innovative medical solutions. It employs a range of modalities, including pharmaceuticals, medical devices, and artificial intelligence, to address challenges within the healthcare sector. By integrating these diverse approaches, Renascience aims to create effective interventions that enhance patient care and improve health outcomes.

JUNTEN BIO is a company is to develop new technologies in the field of regenerative medicine.

StemRIM is a biotechnology company based in Ibaraki, Japan, founded in 2006. The company specializes in the development of regeneration-guided medicines aimed at treating challenging diseases such as epidermolysis bullosa, cerebral infarction, and myocardial infarction. StemRIM's innovative approach involves mobilizing the body's own stem cells to target injured or diseased tissues without the need for extraction. Their product portfolio includes PJ1 regeneration induction medicine using HMGB1 peptides, PJ2 and PJ3 regeneration-inducing drugs and proteins, as well as the PJ4 therapeutic autologous cell collection device and PJ5 stem cell gene therapy technology. Through its research and development efforts, StemRIM seeks to advance the field of regenerative medicine and provide effective treatment options for patients with intractable conditions.

Noile-Immune Biotech Inc, founded in 2015 and based in Minato-ku, Japan, focuses on the research and development of innovative cancer immunotherapies, particularly utilizing CAR-T cell therapy. The company aims to advance treatment options for cancer patients by harnessing the potential of this cutting-edge technology. As a key player in the field, Noile-Immune Biotech is committed to becoming a leader in the next generation of cancer immunotherapy solutions.

Renascience is a pharmaceuticals company focused on the research and development of innovative medical solutions. It employs a range of modalities, including pharmaceuticals, medical devices, and artificial intelligence, to address challenges within the healthcare sector. By integrating these diverse approaches, Renascience aims to create effective interventions that enhance patient care and improve health outcomes.

Aprinoia Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative imaging-based diagnostic tools and therapies for neurological diseases, particularly Alzheimer's disease and tauopathies. Established in 2015 and headquartered in Taipei, Taiwan, with additional facilities in China and Japan, the company specializes in creating diagnostic tracers, including 18F-PM-PBB3 for tau positron-emission tomography (PET) imaging, which aids in identifying tauopathies and supports the development of corresponding treatments. Aprinoia Therapeutics aims to enhance the detection, progression monitoring, and treatment of neurodegenerative conditions such as Alzheimer's, Parkinson's, and dementia through its advanced diagnostic and therapeutic platforms, ultimately striving to improve patient outcomes and brain health.

Momotaro-Gene Inc., a biotechology company, develops tumor-suppressor genes for cancer treatment. It offers reduced expression in immortalized cells (REIC) for cancer therapeutic gene and interleukin (I L-12) for cancer immunostimulant. The company was founded in 2007 and is based in Okayama, Japan.

BONAC Corporation focuses on the research, development, manufacturing, and commercialization of nucleic acid pharmaceutical products, utilizing advanced nucleic acid platform technology. Established in 2010 and headquartered in Kurume, Japan, with an office in Tokyo, the company specializes in the production and sale of nucleic acid ingredients. BONAC offers a comprehensive suite of services that includes drug substance manufacturing and support for drug development, aiming to facilitate access to innovative drug substances for pharmaceutical and cosmetic manufacturers. Through its efforts, BONAC addresses unmet medical needs by advancing RNA technology and developing effective nucleic acid medicines.